Back to top
more

Argenx (ARGX)

(Real Time Quote from BATS)

$375.55 USD

375.55
79,588

+0.26 (0.07%)

Updated Apr 30, 2024 03:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

by Zacks Equity Research

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.

argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

by Zacks Equity Research

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.

Why Earnings Season Could Be Great for argenx (ARGX)

by Zacks Equity Research

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sundeep Ganoria headshot

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Sundeep Ganoria

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.

argenex SE (ARGX) Upgraded to Buy: Here's Why

by Zacks Equity Research

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and argenex SE (ARGX) have performed compared to their sector so far this year.

Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

Here's Why argenex SE (ARGX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug

by Zacks Equity Research

Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.

Best Momentum Stocks to Buy for August 3rd

by Zacks Equity Research

SSB, XOM and ARGX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 3, 2022.

Is McKesson (MCK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.

Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.

Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?

by Zacks Equity Research

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.

5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio

by Zacks Equity Research

We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.

Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?

by Zacks Equity Research

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.

    Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition

    by Zacks Equity Research

    Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.

    argenx (ARGX) Up on Positive Autoimmune Disorder Study Data

    by Zacks Equity Research

    argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.

    Should You Buy argenx SE (ARGX) Ahead of Earnings?

    by Zacks Equity Research

    argenx SE (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Materialise (MTLS) to Report Q4 Earnings: What's in Store?

    by Zacks Equity Research

    Materialise's (MTLS) fourth-quarter 2021 earnings are likely to have benefited from solid operational performance in all three segments.

    Splunk (SPLK) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Splunk's (SPLK) fourth-quarter fiscal 2022 performance is likely to have benefited from solid demand for cloud-based solutions and customer additions.

    SEMrush (SEMR) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    SEMrush's (SEMR) fourth-quarter 2021 performance is likely to have benefited from growth in user licenses per customer along with strength in product add-ons.